CLASSYS Inc. (KOSDAQ:214150)
47,300
-200 (-0.42%)
Nov 5, 2025, 3:30 PM KST
CLASSYS Revenue
CLASSYS had revenue of 83.28B KRW in the quarter ending June 30, 2025, with 41.78% growth. This brings the company's revenue in the last twelve months to 294.21B, up 43.96% year-over-year. In the year 2024, CLASSYS had annual revenue of 242.94B with 34.87% growth.
Revenue (ttm)
294.21B
Revenue Growth
+43.96%
P/S Ratio
10.53
Revenue / Employee
746.74M
Employees
394
Market Cap
3.10T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 242.94B | 62.82B | 34.87% |
| Dec 31, 2023 | 180.12B | 38.32B | 27.02% |
| Dec 31, 2022 | 141.80B | 41.21B | 40.96% |
| Dec 31, 2021 | 100.60B | 24.14B | 31.57% |
| Dec 31, 2020 | 76.46B | -4.67B | -5.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |